Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from the total KEYNOTE-052 study population.

出版年份 2017 全文链接

标题

作者

关键词

出版物

Volume 35, Issue 6_suppl, Pages 284-284

出版商

American Society of Clinical Oncology (ASCO)

发表日期

2017-03-29

DOI

10.1200/jco.2017.35.6_suppl.284

Discuss science. Find collaborators. Network.

Join a conversation

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now